SpringWorks Therapeutics 주식 (NASDAQ: SWTX)

에 대한 최신 뉴스 SpringWorks Therapeutics (NASDAQ:SWTX) 주식

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

Uber Weride

Equities

Mid Cap

News

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Plug Power hardware.

CPRI

NARI

PAYX

PLUG

PYCR

이들 11개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 이나리 메디컬(NASDAQ:NARI)의 주식은 스트라이커(NYSE:SYK)이 주당 80달러 또는 약 49억 달러의 지분 가치를 제시하며 회사를 인수하기로 합의한 후 53.07% 급등했다.

플러그 파워, 카프리 및 프론트라인은 지난주 최대 상승한 중형주 (1월 6일-10일)

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Technology giant Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) could be one of the most-watched stocks for the week when the company reports third-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday</a>.
Here are the earnings estimates, a look at what analysts are saying and key items to watch.
Earnings Estimates: Analysts expect Microsoft to report third-quarter revenue of $68.44 billion, up from $61.86 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">from Benzinga Pro.</a>
The company has beaten analyst revenue estimates in eight straight quarters and nine of the last 10 quarters overall.
Analysts expect Microsoft to report third-quarter earnings per share of $3.22, up from $2.94 in last year's third quarter. Microsoft has beaten analyst earnings per share estimates in 10 straight quarters.
What Experts Are Saying: Freedom Capital Markets Chief Global Strategist Jay Woods emphasized the importance of Microsoft's financial results in a weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
"Considering we are dealing with the top market caps in the world, their price impact will move the markets. All but META are in both the Dow and S&amp;P 500 and all four stocks are the top holdings in their specific sector ETFs," Woods said of Meta Platforms, Microsoft, Apple and Amazon.com.
Woods said all four have recently hit bear market territory and have "much room to reverse to get back to old highs."
"MSFT shares are 16% below their highs and flat for the last year. The company continues to spend on AI and investors want to see how this investment is being integrated into their product suite and what impact that will have on revenue."
Woods said another key focus will be on Microsoft's cloud services performance. "Growth with Azure is expected to bolster its cloud operations.&#8221;
Wedbush analyst Dan Ives <a href="https://www.benzinga.com/25/04/45001386/dan-ives-software-the-only-safety-blanket-amid-the-storm-of-tariffs">recently highlighted</a> Microsoft as one of several software stocks that could be part of what he called a "security blanket" from the "Category 5" storm that includes trade wars, tariffs and geopolitical uncertainties.
He noted that with the supply chain "visibly clouded," companies with software are a safer bet, with Microsoft being one example. The analyst also said the "AI party is just getting started," with a prediction of $1 trillion in incremental spending for the sector over the next decade helping companies like Microsoft.
Goldman Sachs analyst Kash Rangan was one of several analysts to <a href="https://www.benzinga.com/25/04/44977884/goldman-trims-microsoft-price-target-to-450-but-sticks-with-bullish-gen-ai-growth-thesis">cut the price target</a> on Microsoft stock ahead of earnings, taking the target from $500 to $400 while reiterating a Buy rating.
The analyst said Microsoft still remains a compelling name in software but is concerned about several potential near-term headwinds.
Rangan is specifically cautious about Microsoft's guidance as there could be "some downside risk" if non-AI growth slows.
KeyBanc Capital analyst Jackson Ader<a href="https://www.benzinga.com/analyst-ratings/downgrades/25/04/44874447/microsoft-analyst-lowers-rating-flags-slower-growth-flat-valuation-outlook" target="_blank" rel="noopener"> recently downgraded Microsoft </a>stock from &#8220;Overweight&#8221; to &#8220;Sector Weight&#8221; with no price target.
The analyst said some durable macro themes could play out during the on-calendar season for Microsoft, with caution in the company's guidance.
While the current quarter was holding up fine, conversations with Microsoft marketing partners indicated concerns for the rest of the year, Ader said.
Key Items to Watch: Cloud and AI are likely to be the most-watched segments in Microsoft's earnings report, along with items to watch for management commentary.
In <a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">the second quarter</a>, Microsoft's Intelligent Cloud segment saw revenue increase by 19% year-over-year.
"We are innovating across our tech stack and helping customers unlock the full ROI of AI to capture the massive opportunity ahead," Microsoft CEO Satya Nadella said after second-quarter results.
Nadella said Microsoft's AI business had surpassed an annual run rate of $13 billion.
As mentioned by Woods, Microsoft could be one of the most important stocks for the week due to its presence in several top indexes. The stock report could make the SPDR S&amp;P 500 ETF Trust (SPY) and SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) ETFs volatile.
Microsoft is the second-largest holding in the SPY at 6.2% of assets and is the third-largest holding in the DIA at 6.0% of assets.
MSFT Price Action: Microsoft stock is up 0.6% to $393.35 on Tuesday versus a 52-week trading range of $344.79 to $468.35. Microsoft stock is down 6.0% year-to-date in 2025 and down 2.2% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45043339/stock-of-the-day-will-microsoft-bring-the-entire-market-higher">Stock Of The Day: Will Microsoft Take The Entire Market Higher?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Tech

SPDR Dow Jones Industrial Average ETF Trust

MSFT

Microsoft Q3 Earnings Preview: Cloud, AI, Guidance Top Items Analysts Highlight To Watch

WIIM

MSTR

Strategy shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a price target of $480.

Progressive shares are trading higher after Morgan Stanley raised its price target on the stock from $310 to $320 and maintained an Overweight rating.

Ecolab shares are trading higher after the company issued FY25 adjusted EPS guidance with its midpoint above estimates.

PANW

Palo Alto Networks shares are trading higher after the company announced it partnered with AT&T to introduce secure connectivity solutions for business customers.

<a href="https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e</a>

'Electronic Arts Lays Off Hundreds, Cancels 'Titanfall' Game' - Bloomberg

ANET

Arista Networks shares are trading higher after Rosenblatt upgraded the stock from Sell to Neutral and raised its price target from $55 to $85.

S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) shares are trading higher on Tuesday, after the company <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">reported first-quarter results</a>.
S&amp;P Global reported <a target="_blank" href="https://s29.q4cdn.com/690959130/files/doc_financials/2025/q1/S-P-Global-1Q-2025-Earnings-Release-4-29-2025.pdf" rel="noreferrer noopener">quarterly </a>adjusted earnings per share of $4.37, beating the analyst consensus estimate of $4.19.
Quarterly sales of $3.78 billion (up 8% year over year) outpaced the street view of $3.70 billion. Revenue from subscription products increased 7%.
Adjusted net income for the first quarter increased 7% to $1.344 billion. Higher net income was driven primarily by strong growth in Ratings and Indices on both a GAAP and adjusted basis.
The company&#8217;s quarterly adjusted operating margin increased 100 basis points to 41.8%, driving 9% growth in adjusted EPS.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45038784/s-p-500-a-kite-dancing-in-a-hurricane" rel="noreferrer noopener">S&amp;P 500: A Kite Dancing In A Hurricane</a>
In a separate release, the firm announced its intent to separate S&amp;P Global Mobility from S&amp;P Global to drive long-term value creation. The planned separation is expected to result in Mobility <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45063179/s-p-global-announces-intent-to-separate-mobility-segment-into-standalone-public-company" rel="noreferrer noopener">becoming a standalone public company.</a>
In fiscal year 2024, the Mobility segment generated&nbsp;$1.6 billion&nbsp;in revenue, a year-over-year increase of approximately 8%. S&amp;P Global expects to complete the separation within 12 to 18 months.
Outlook: S&amp;P Global updated its FY2025 adjusted EPS guidance to $16.75–$17.25, compared to the previous $17.00–$17.25 range.
The new EPS outlook compares with the $17.00 analyst estimate.
It also lowered its FY2025 sales forecast to $14.78 billion–$15.06 billion, down from $14.92 billion–$15.20 billion.
The revised sales guidance compares with the $14.99 billion analyst estimate.
Price Action: SPGI shares are trading higher by 3.2% to $494.88 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000" target="_blank" rel="noreferrer noopener">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a></li>
</ul>
Photo: Shutterstock

Markets

General

SPGI

S&P Global Shares Rise On Strong Earnings, Mobility Spinoff Plan

Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) today announced that its Board of Directors has appointed W. Paul Bowers as its Independent Board Chair, effective April 29. Mr. Bowers has been an Independent Director on Exelon's Board since 2021. The change comes at the retirement of outgoing Board Chair, John F. Young, who has served in the role since 2022.
 &nbsp;

Management

Exelon Board Appoints Paul Bowers As Independent Board Chair, Effective April 29

Major Wall Street investment banks are divided over how the dollar will move from here, yet much clarity could be just days away as a deluge of <a href="https://www.benzinga.com/news/econ-s">key economic data looms.</a>
In an outlook shared with clients last week, Wells Fargo's economics team, led by Nick Bennenbroek, expressed a bullish short-term stance on the U.S. dollar, calling the recent wave of depreciation &#8220;tactical&#8221; rather than the beginning of a structural trend.
"We expect the U.S. dollar to rebound in the immediate period ahead," the analysts said, suggesting the dollar will remain fundamentally supported before resuming trend strength into 2026.
<h3 class="wp-block-heading">Bearish Positioning Builds As Speculators Eye US Economic Weakness</h3>
 Speculative net short positions against the greenback — measured across 10 major currencies and the Dollar Index (DXY) — surged to $40 billion last week, the highest level since October 2023, according to Commodity Futures Trading Commission data.
The Dollar Index, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), has dropped 8% year-to-date, reaching its most oversold levels since December 2020 last week.
Technically, it is now 5.5% below its 200-day and 4.5% below its 50-day moving averages, underscoring how aggressive the recent selloff has been.
Wells Fargo indicated that unusual dynamics are pressuring the dollar, particularly the political noise and tariff volatility emanating from the U.S. 
"With the source of policy uncertainty and volatility coming out of the United States, market participants have sold dollar-denominated assets and moved away from Treasuries," they said. 
Yet, the team described this as &#8220;a transitory phenomenon,&#8221; not a fundamental reassessment of U.S. assets.
<h3 class="wp-block-heading">Goldman Sachs Sees Further Dollar Weakness Ahead</h3>
Over at Goldman Sachs, foreign exchange analyst Kamakshya Trivedi took the opposite side of the trade.
"Even after a swift move in recent weeks, we believe that the dollar has further to fall," Trivedi said. 
The investment bank highlights that the underperformance of U.S. assets and the reduction in global investors' enthusiasm for unhedged dollar assets could trigger a longer-lasting decline in the greenback.
Trivedi emphasized that investors may be overestimating the impact of short-term positioning while underestimating the structural reallocation already underway. 
"We are more focused on the likely shift in future allocations," he said, citing historical parallels where changes in investor appetite led to persistent exchange rate moves.
Goldman's concern is compounded by ongoing uncertainty around U.S. trade and monetary policy. 
While President Donald Trump's recent statements hint at potential tariff rollbacks and efforts to reassure markets — including backing off pressure on the Fed — the bank is unconvinced these efforts will quickly restore investor confidence.
<h3 class="wp-block-heading">Dollar Direction Hinges On Upcoming Macro Data</h3>
The next few trading days could be decisive for the dollar&#8217;s short-term fate, with several high-impact U.S. economic reports on deck:
<ul>
<li>Q1 2025 GDP (Wednesday): Expected to slow sharply from 2.8% in Q4 2024 to 0.4%, according to median economist consensus tracked by TradingEconomics.</li>
<li>Personal Consumption Expenditure (PCE) price index (Wednesday): Fed's preferred inflation gauge expected to cool to from 2.5% to 2.2% in March, with core PCE dropping from 2.8% to 2.6%</li>
<li>April Jobs Report (Friday): Forecasts see nonfarm payrolls at 135,000, down from 228,000, with unemployment steady at 4.2%</li>
</ul>
If the data confirm a softening U.S. economy, it could validate Goldman Sachs' bearish thesis, especially as investors price in earlier and deeper Federal Reserve rate cuts. 
On the flip side, any surprise economic resilience in jobs or inflation could lend weight to Wells Fargo's tactical dollar rebound call.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Dollar Under Pressure: Wall Street Split Widens Ahead Of High-Stakes US Data

Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) has seen its stock climb 50% to $1.34 over the past week following a series of company announcements.
What To Know: The California-based electric vehicle maker recently <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">appointed</a> founder YT Jia as Co-CEO alongside current CEO Matthias Aydt, signaling a new dual-leadership structure. Jia will oversee finance, legal and supply chain operations in addition to his current responsibilities. His new equity incentive package is tied to market cap and stock performance.
At the company's recent "FF Stockholder Community and FX Co-Creation Day" in Los Angeles, Jia outlined strategic goals including launching the first FX model by end of 2025, achieving positive gross margin and operating cash flow and pursuing global AI and AIEV M&amp;A initiatives. 
California <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">political figures</a> including former Assembly Speaker Anthony Rendon and Hanford Mayor Lou Martinez expressed public support for the company's transformation efforts. 
Faraday Future emphasized its intent to maximize stakeholder value and resist illegal short-selling as it executes its Global Bridge Strategy.
Read Also: <a href="https://www.benzinga.com/news/25/04/45078865/d-wave-quantum-qbts-stock-falls-amid-valuation-critique-by-kerrisdale-capital">D-Wave Quantum Stock Falls Amid Valuation Critique By Kerrisdale Capital</a>
<h2 class="wp-block-heading">How To Buy FFAI Stock</h2>
By now you're likely curious about how to participate in the market for Faraday Future &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Faraday Future, which is trading at $1.33 as of publishing time, $100 would buy you 75.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FFAI has a 52-week high of and a 52-week low of

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future (FFAI) Shares Surge 50% Amid Leadership Changes And Strategic Updates

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2F&amp;esheet=54246103&amp;newsitemid=20250429590949&amp;lan=en-US&amp;anchor=BeiGene&amp;index=1&amp;md5=0c09798a0c67c852789b965c290809ae">BeiGene</a>, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.
On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA&#xAE; (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene's petition to institute the PGR. The USPTO's Final Written Decision is appealable by Pharmacyclics.
Commenting on the ruling, BeiGene General Counsel Chan Lee said: "We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today's decision reinforces our belief that Pharmacyclics' ‘803 patent is overly broad and invalid. BeiGene is confident in the strength of our intellectual property supporting BRUKINSA, a clearly differentiated and independently developed medicine. With approvals in more than 70 countries and regions for the treatment of multiple B-cell malignancies, BRUKINSA continues to set a new standard of care for patients worldwide."

USPTO Renders Final Decision, Invalidating All Challenged Pharmacyclics Patent Claims Against BeiGene

SoFi Technologies Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) stock price gained Tuesday after it reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45062395/sofi-reports-first-quarter-2025-with-record-net-revenue-of-772-million-record-member-and-product-g" rel="noreferrer noopener">first-quarter 2025</a> earnings on Tuesday. Here's a look at the&nbsp;key metrics from the quarter.
The company reported quarterly adjusted sales of $770.72 million, beating analyst estimates of $739.04 million. The company reported quarterly adjusted earnings of 6 cents per share, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating&nbsp;analyst estimates of</a> 4 cents per share.
Adjusted revenue rose 33% year-over-year. Financial services revenue increased by 101% year-over-year, lending segment revenue increased by 25% year-over-year, and technology platform revenue increased by 10% year-over-year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44989977/sofi-stock-is-up-11-this-week-whats-going-on" rel="noreferrer noopener">SoFi Stock Jumps as It Opens AI and Private Market Investments to Everyday Investors</a>
Net interest income of&nbsp;$498.7 million&nbsp;was up 24%&nbsp;year-over-year, driven by a&nbsp;23%&nbsp;growth in average interest-earning assets and an 82 basis points decrease in cost of funds.
SoFi added 800,000 new members in the quarter, bringing total members up to 10.9 million, up 34% year-over-year. Product additions totaled nearly 1.2 million in the quarter.
SoFi&nbsp;CEO&nbsp;Anthony Noto&nbsp;<a target="_blank" href="https://www.cnbc.com/2025/04/29/sofi-crypto-investing.html" rel="noreferrer noopener">told</a> CNBC in an interview Tuesday that the fintech bank will bring back cryptocurrency investing this year following a shift in the regulatory landscape under the Trump administration. It had to dump crypto investing in late 2023 to bag a bank charter.&nbsp;
Outlook: In the second quarter of 2025, SoFi expects to generate $785 million—$805 million of adjusted net revenue versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of</a> $783.02 million, $200 million—$210 million of adjusted EBITDA, $60 million—$70 million of GAAP net income and $0.05-$0.06 of GAAP EPS (below the estimate of $0.06).
For the full year 2025, the company expects adjusted net revenue of $3.235 billion-$3.310 billion (<a href="https://www.benzinga.com/25/01/43233747/sofi-q4-earnings-24-revenue-increase-adds-785k-members-ceo-highlights-strong-financial-services-momentum-projects-23-26-revenue-growth-for-2025" target="_blank" rel="noreferrer noopener">prior $3.200 billion-$3.275 billion</a>) versus analyst consensus of $3.200 billion, which equates to approximately 24%-27% (prior 23%-26%) year-over-year growth.
Sofi anticipates an adjusted EBITDA of $875 million-$895 million (prior $845 million-$865 million), GAAP net income of $320 million- $330 million (prior $285 million-$305 million), and GAAP EPS of $0.27-$0.28 (prior $0.25 to $0.27) versus consensus of $0.26. 
Price Action: SOFI stock is up 2.84% at $13.58 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in" target="_blank" rel="noreferrer noopener">Cramer Cautions on SoFi Stock After Weak 2025 Profit Outlook</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Guidance

SOFI

SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback

Vacasa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) ("Vacasa" or the "Company"), a leading vacation rental management platform in North America, today announced that its stockholders have approved the proposed merger with Casago (the "Merger").
On April 29, 2025, Vacasa held a special meeting of the Company's stockholders (the "Special Meeting") to vote on a proposal (the "Merger Agreement Proposal") to adopt the Agreement and Plan of Merger, dated as of December 30, 2024, as amended by Amendment No. 1 thereto, dated as of March 17, 2025, and by Amendment No. 2 thereto, dated as of March 28, 2025. At the Special Meeting, approximately 69% of the Company's Class A common stock, 96% of the Company's Class B common stock and 72% of the Company's Class A common stock and Class B common stock, voting together as a single class, voted in favor of the Merger Agreement Proposal.
The Company expects closing of the Merger to occur at 11:59 pm ET on April 30, 2025, subject to the satisfaction or waiver of the remaining closing conditions.

VCSA

Vacasa Stockholders Approve Proposed Merger With Casago

Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares fell 13.2% to $12.85 during Tuesday&#8217;s session after the solar-grade polysilicon producer reported <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">worse-than-expected</a> first-quarter results, signaling possible industry struggles.
What To Know: The company posted an adjusted net loss of 80 cents per ADS, wider than analyst expectations of a 69 cent loss. Revenue dropped 70% year-over-year to $123.9 million, missing the $182.1 million consensus. The sharp decline was driven by lower sales volumes and weak pricing, amid persistent overcapacity and muted demand in the solar PV market.
Gross margin plunged to -65.8% from +17.4% a year ago, with a gross loss of $81.5 million. Polysilicon average selling prices dropped to $4.37/kg, below both production and cash costs. Despite losses, Daqo&#8217;s balance sheet shows $2.15 billion in liquid assets and <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">no financial debt</a>.
CEO Xiang Xu said the company ran at 33% capacity to manage inventory and mitigate low prices. Looking ahead, Daqo expects second-quarter polysilicon output of 25,000–28,000 MT. Management remains confident in long-term prospects, citing cost leadership, new technologies and China&#8217;s push for solar expansion.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45073201/plug-power-stock-is-trending-tuesday-whats-going-on">Plug Power Stock Is Trending Tuesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy DQ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Daqo New Energy&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DQ has a 52-week high of $30.85 and a 52-week low of $12.40.

Daqo New Energy (DQ) Stock Slides On Steep Revenue, Earnings Miss In Q1

Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/n45062385/the-sherwin-williams-company-reports-2025-first-quarter-financial-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $5.31 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $5.4 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $2.25, versus estimates of $2.16 per share</li>
</ul>
Sherwin-Williams said total sales declined 1.1% year-over-year. Consumer Brands Group sales fell 6% year-over-year, primarily due to &#8220;soft&#8221; DIY demand in North America. Performance Coating Group sales were down 4.8% in the quarter. Paint Stores Group sales fared better, seeing 1.2% sales growth during the period, primarily driven by selling price increases. 
The company returned&nbsp;$552.1 million&nbsp;to shareholders in the first quarter in the form of dividends and repurchases. Sherwin-Williams ended the period with $199.8 million in cash and cash equivalents.
&#8220;In a demand environment that remained choppy as we anticipated, Sherwin-Williams continued to execute our strategy and delivered solid&nbsp;first quarter&nbsp;results driven by gross margin expansion and good cost control,&#8221; said Heidi Petz, chair, president and CEO of Sherwin-Williams.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45061797/us-stock-futures-edge-higher-tuesday-expert-warns-of-perfect-volatility-storm-with-major-earnings-and-economic-data-due-this-week">US Stock Futures Edge Higher Tuesday: Expert Warns Of &#8216;Perfect Volatility Storm&#8217; With Major Earnings And Economic Data Due This Week</a>
Guidance: Sherwin-Williams expects second-quarter revenue to be up or down in the low-single digit percentage range. The company guided for full-year 2025 net sales growth in the low-single digit percentage range. 
Sherwin-Williams also expects full-year adjusted earnings of $11.65 to $12.05 per share versus estimates of $11.90 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;We continue to expect demand softness to persist in several end markets well into the second half of the year. Regarding current tariffs, it&#8217;s important to remember that the largest portion of our revenue is in&nbsp;the United States, and the majority of our raw materials are sourced in the regions where we manufacture. In a macro-economic environment that remains turbulent, we are focused on being a source of stability and reliability for our customers, providing them with differentiated solutions that increase their productivity and profitability,&#8221; Petz said.
SHW Price Action: <a href="http://benzinga.com/quote/SHW">Sherwin-Williams shares</a> were up 5.46% at $350.33 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Sherwin-Williams Reports Mixed Q1 Results In 'Choppy' Demand Environment

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">epidermolysis bullosa (RDEB)</a>.
RDEB is&nbsp;a severe, genetically inherited skin disorder characterized by blistering and skin fragility, often presenting at birth.
Zevaskyn is the only FDA-approved product to treat RDEB wounds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061116/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-p" rel="noreferrer noopener">with a single application</a>.
Zevaskyn consists of a patient&#8217;s skin cells (keratinocytes) genetically modified to produce functional Type VII collagen. Zevaskyn sheets are surgically applied to the patient&#8217;s wounded areas. In a single application, up to 12 credit card-sized sheets can be combined to cover large areas or applied to multiple distinct wounds, allowing for significant coverage of affected body areas.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Zevaskyn is expected to be available beginning in the third quarter of 2025 through Zevaskyn Qualified Treatment Centers.
The FDA approval is based on the pivotal Phase 3 VIITAL study, which met its two co-primary efficacy endpoints, demonstrating statistically significant healing of 50% or more from baseline in large chronic RDEB wounds and pain reduction from baseline as assessed by the Wong-Baker FACES scale, as evaluated at six months after treatment.
Across 43 large and chronic wounds treated with a single application of Zevaskyn, 81% of wounds showed 50% or more healing (P&lt;0.0001) as evaluated at six months, compared to 16% in 43 matched control wounds treated with standard-of-care.
The most common adverse events were observed in fewer than 5% of patients, including procedural pain and itch.
The Phase 1/2a study of Zevaskyn, which involved 38 chronic wounds across seven patients, showed that a single surgical application of Zevaskyn was associated with long-term improvement at treated sites over a median follow-up of 6.9 years, ranging from 4 to 8 years.
Last April, the FDA issued a Complete Response Letter (CRL) in response to the company&#8217;s Biologics License Application (BLA) for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38380100/fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink" rel="noreferrer noopener">pz-cel for RDEB</a>.&nbsp;
The FDA noted that certain additional information&nbsp;was needed&nbsp;to&nbsp;satisfy Chemistry Manufacturing and Controls (CMC) requirements.&nbsp;
Price Action: ABEO stock is up 2.34% at $5.46 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides</a></li>
</ul>
Photo via Shutterstock

Health Care

ABEO

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Sleep Number will report an earnings per share (EPS) of $-0.05. 
Investors in Sleep Number are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 41.89% drop in the share price the next day.
Here's a look at Sleep Number's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.17</td>
<td>-0.37</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.14</td>
<td>-0.22</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-42.0%</td>
<td>4.0%</td>
<td>20.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953405_0.png" alt="eps graph" />
<h3>Sleep Number Share Price Analysis</h3>
Shares of Sleep Number were trading at $7.4 as of April 28. Over the last 52-week period, shares are down 43.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SNBR/earnings">To track all earnings releases for Sleep Number visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNBR

Earnings Outlook For Sleep Number

Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Oatly Group to report an earnings per share (EPS) of $-0.84.
The market awaits Oatly Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $1.60, leading to a 37.69% increase in the share price on the subsequent day.
Here's a look at Oatly Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.4</td>
<td>-1.2</td>
<td>-1.4</td>
<td>-1.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3</td>
<td>-1.2</td>
<td>-1</td>
<td>-1.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>38.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953397_0.png" alt="eps graph" />
<h3>Tracking Oatly Group's Stock Performance</h3>
Shares of Oatly Group were trading at $10.0 as of April 28. Over the last 52-week period, shares are down 55.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OTLY/earnings">To track all earnings releases for Oatly Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OTLY

Oatly Group Earnings Preview

<ul>
<li>IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.</li>
<li>IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV.</li>
<li>IPH4502 showed strong preclinical activity across multiple tumor types, including triple-negative breast cancer, head and neck, and esophageal cancers, supporting its potential for broad clinical application.</li>
</ul>
Innate Pharma SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/IPH#PARIS">IPH</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

IPHA

PARIS:IPH

Innate Pharma Presents New Preclinical Data For IPH4502 AACR Annual Meeting 2025; IPH4502 Shows Strong Preclinical Activity Across Multiple Tumor Types

Press Releases

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareholders

ALBT

BRDG

RDUS

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alkermes

Alvotech

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Grifols, S.A. - American Depositary Shares

Grifols

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Guggenheim

TD Cowen

Barclays

HC Wainwright & Co.

Wedbush

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 위라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 43.45% 상승했다. 이는 트럼프 대통령이 중국에서 오는 $800 이하의 소포에 대한 관세를 연기했다고 보도된 후 발생한 일이다. 또한, 중국의 딥시크(DeepSeek) AI 모델에 대한 낙관론도 최근 주가를 끌어올렸다.
3. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식이 42.58% 상승했다. 이는 머크 그룹(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>)가 회사를 인수하기 위한 고급 논의를 진행 중이라고 발표한 후 발생한 일이다.
4. 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)의 주식이 40.59% 증가했다.
5. 세이블 오프쇼어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>)의 주식이 39.09% 상승했다.
6. 진DX 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식이 28.23% 상승했다. 이는 회사가 울트라래피드 전장유전체 시퀀싱(UltraRapid Whole Genome Sequencing)을 발표하여 48시간 내에 실행 가능한 결과를 제공한다고 발표한 후 발생한 일이다.
7. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식이 28.22% 상승했다. 이는 지난 주 중국의 딥시크 AI 모델과 관련된 AI 경쟁 우려로 하락한 후 반등 가능성이 제기된 것으로 보인다.
8. 인스페리티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>)의 주식이 25.99% 증가했다. 이는 회사가 예상보다 좋은 4분기 결과를 발표한 후 발생한 일이다.
9. 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)의 주식이 25.21% 상승했다. 이는 회사가 예상보다 좋은 4분기 재무 결과를 발표한 후 여러 애널리스트들이 주가 전망을 상향 조정한 후 발생한 일이다.
10. 액섬 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)의 주식이 24.01% 상승했다. 이는 회사가 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)과의 모든 특허 소송을 해결하기 위한 합의에 도달한 후 발생한 일이다. 여러 애널리스트들이 주가 전망을 상향 조정했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%9D%B8%ED%85%94-%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-%EB%B0%8F-cvs-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%83%81%EC%8A%B9%ED%95%9C-12/" target="_blank" rel="noopener">슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)</a>
<a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B3%A0%EB%8C%80%EB%94%94-%EB%B0%8F-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C-%EB%8D%B0%EC%8A%A4%ED%81%AC%EB%8A%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-11/" target="_blank" rel="noopener">레딧, 고대디 및 트레이드 데스크는 등 지난주 하락한 11개의 대형주 (2월 10일~2월 14일)</a>
사진 출처: WeRide
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이나리 메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>)의 주식은 스트라이커(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>)이 주당 80달러 또는 약 49억 달러의 지분 가치를 제시하며 회사를 인수하기로 합의한 후 53.07% 급등했다.
2. 유니퍼스트 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42878530" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 29.58% 상승했다.
3. 플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주식은 미국 재무부가 45V 생산세액 공제에 대한 최종 지침을 발표하여 <a href="https://www.benzinga.com/topic/hydrogen" target="_blank" rel="noreferrer noopener">더 친환경적인 수소 미래</a>를 위한 기반을 마련한 후 23.18% 상승했다. 플러그 파워는 이로 인해 혜택을 받을 것으로 예상된다.
4. 페이코 HCM(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>)의 주식은 회사가 페이첵스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)에 의해 약 41억 달러의 기업 가치를 지닌 현금 거래로 전액 인수될 것이라고 발표한 후 20.77% 상승했다.
5. MP 머티리얼즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>)의 주식은 20.50% 상승했다.
6. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식은 인수 관심 소문 속에서 19.18% 상승했다.
7. 프론트라인 Plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)의 주식은 아마도 도널드 트럼프 당선자가 바이든 대통령의 해양 시추 금지 조치를 철회하겠다고 말한 후 17.29% 상승했을 것이다.
8. 가든트 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)의 주식은 15.53% 상승했다. 회사는 쉴드(Shield) 다중암 검출 테스트가 <a href="https://www.benzinga.com//node/42842047" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">국립암연구소(National Cancer Institute)의 뱅가드 연구(Vanguard Study)</a>에 선정되었다고 밝혔다.
9. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식은 15.40% 상승했다.
10. 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>)의 주식은 프라다가 카프리 베르사체의 잠재적 구매자가 될 수 있다는 보도가 나오는 가운데 주가는 15.04% 상승했다.
11. 이퀴녹스 골드(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EQX#AMEX">EQX</a>)의 주식은 14.88% 상승했다. 회사는 4분기에 213,960온스의 금을 생산했으며, <a href="https://www.benzinga.com//node/42888339" target="_blank" rel="noreferrer noopener">2024년에는 621,870온스를 생산</a>했다고 보고했다.
사진 제공: Plug Power
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EA%B7%B8%EB%A6%B0%EC%8A%A4-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%A0-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">월그린스, 마이크론, 델타 항공은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 6일-10일)</a></li>
</ul>
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%AA%A8%EB%B9%8C%EC%95%84%EC%9D%B4-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EB%B0%8F-%EC%96%B4%ED%8E%8C-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4/" target="_blank" rel="noopener">모빌아이, 팔란티어 및 어펌 지난주 최악의 성과를 보인 9개 대형주 중 일부 (1월 6일-10일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

SpringWorks Therapeutics

뉴스

에 대한 최신 뉴스 SpringWorks Therapeutics (NASDAQ:SWTX) 주식

일요일, 2월 16, 2025

일요일, 1월 12, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌